We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Digital Pathology Approach Helps Identify New NSCLC Biomarkers

By LabMedica International staff writers
Posted on 21 Jun 2023

Lung cancer is the leading cause of cancer-related deaths among both genders globally, with a five-year survival rate standing at a mere 18%. More...

Non-small cell lung cancer (NSCLC), divided further into adenocarcinoma, squamous cell carcinoma, and a few rarer types, is the most common diagnosis for these patients. Emerging evidence underscores the critical role of the collagen fiber-rich microenvironment surrounding cancer cells in the growth of these cancers and other solid tumors. In this tumor context, high type I collagen expression is linked to poor prognosis and higher metastasis risk. This association suggests that fibrillar collagens could serve as a key source of cancer-relevant biomarkers and has sparked interest in deciphering their roles in tumor development.

In response to this challenge, researchers at the University of Barcelona (Barcelona, Spain) and the Institute of Bioengineering of Catalonia (IBEC, (Barcelona, Spain) have developed and validated a novel digital pathology approach that quantitatively analyzes collagen fibers in tissue samples from NSCLC patients. The approach utilizes digitized images of patient biopsies stained with a dye named picrosirius red (PSR) and imaged with polarized light. The researchers employed the open-source software CT-FIRE to automatically segment individual fibers in the images and quantify critical characteristics like length, width, or straightness.

The team applied this methodology to analyze 195 samples from patients with adenocarcinoma and squamous cell carcinoma. The findings suggest that fiber straightness could serve as a potential disease biomarker, while high density could indicate a poor prognosis. Interestingly, the prognostic relevance of collagen density appears independent of the clinical tumor stage, suggesting that collagen fiber analysis provides additional crucial information. The new methodology also enabled the comparison of collagen fibers in patient tissue samples with non-cancerous tissue samples. This allowed, for the first time, a quantitative description of the changes occurring in collagen organization in NSCLC. The findings indicate that tumor tissue samples showed an increase in straightness, length, and width, suggestive of abnormal tissue stiffening, especially in adenocarcinoma patients. According to the researchers, this stiffening could be related to various mechanisms that help the tumor evade the immune response, thereby potentially facilitating tumor progression in this type of cancer.

“Our new tool can improve the clinical management of surgical patients with this type of cancer, since it identifies those at an increased risk of relapse and, therefore, can benefit from a comprehensive monitoring and even neoadjuvant therapies (complementary to the main treatment)”, noted Jordi Alcaraz, lecturer at the Faculty of Medicine and Health Sciences of the UB and researcher at IBEC.

Related Links:
University of Barcelona 
IBEC 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
New
Laboratory Software
ArtelWare
New
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Colorectal cancer under the microscope (Photo courtesy of Adobe Stock)

Unique Microbial Fingerprint to Improve Diagnosis of Colorectal Cancer

Colorectal cancer is the fourth most common cancer in the UK and the second deadliest. New research has revealed that it carries a unique microbial fingerprint, which could help doctors better understand... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.